Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. 1996

A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
Institute of Clinical Neurology, University of Pisa, Italy.

Various open and controlled studies have confirmed the antimigraine action of flunarizine, while the antimigraine properties of nimodipine are still open to controversy. Moreover, only a few studies include an additional follow-up after discontinuation of migraine prophylaxis with either drug. We carried out a single blind evaluation of the efficacy and tolerance of flunarizine (25 patients) in comparison with nimodipine (25 patients) and the long-term effect after discontinuation of a 6-month treatment. Both medications significantly reduced migraine frequently and severity. Flunarizine was more efficacious than nimodipine in reducing migraine frequency (p < 0.001), pain severity (p < 0.05), migraine index (p < 0.05) and corrected migraine index (p < 0.05). The positive effect lasted 8.4 +/- 4.0 months after discontinuation of flunarizine and 4.9 +/- 3.5 months after nimodipine (p < 0.05). Our results suggest that flunarizine is more effective than nimodipine in the prophylactic treatment of migraine. The positive effect after drug discontinuation lasts longer with flunarizine, compared to nimodipine.

UI MeSH Term Description Entries
D008297 Male Males
D008881 Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) Acute Confusional Migraine,Headache, Migraine,Status Migrainosus,Abdominal Migraine,Cervical Migraine Syndrome,Hemicrania Migraine,Migraine,Migraine Headache,Migraine Variant,Sick Headache,Abdominal Migraines,Acute Confusional Migraines,Cervical Migraine Syndromes,Disorder, Migraine,Disorders, Migraine,Headache, Sick,Headaches, Migraine,Headaches, Sick,Hemicrania Migraines,Migraine Disorder,Migraine Headaches,Migraine Syndrome, Cervical,Migraine Syndromes, Cervical,Migraine Variants,Migraine, Abdominal,Migraine, Acute Confusional,Migraine, Hemicrania,Migraines,Migraines, Abdominal,Migraines, Acute Confusional,Migraines, Hemicrania,Sick Headaches,Variant, Migraine,Variants, Migraine
D009553 Nimodipine A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. Admon,Bay e 9736,Brainal,Calnit,Kenesil,Modus,Nimodipin Hexal,Nimodipin-ISIS,Nimodipino Bayvit,Nimotop,Nymalize,Remontal,Bayvit, Nimodipino,Hexal, Nimodipin,Nimodipin ISIS,e 9736, Bay
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D005260 Female Females
D005444 Flunarizine Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. Flunarizin,Flunarizine Dihydrochloride,Flunarizine Hydrochloride,R-14950,Sibelium,Dihydrochloride, Flunarizine,Hydrochloride, Flunarizine,R 14950,R14950
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
May 1985, Cephalalgia : an international journal of headache,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
October 1983, Acta endocrinologica,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
January 1990, Journal of medicine,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
January 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
January 1997, Movement disorders : official journal of the Movement Disorder Society,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
February 1987, Headache,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
June 2011, Family practice,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
June 1994, Journal of the American College of Nutrition,
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
June 2006, Arerugi = [Allergy],
A Nuti, and C Lucetti, and N Pavese, and G Dell'Agnello, and G Rossi, and U Bonuccelli
January 2017, The American journal of gastroenterology,
Copied contents to your clipboard!